Bengaluru — Moderna said on Tuesday that the US Food and Drug Administration (FDA) granted “fast-track” designation to its experimental coronavirus vaccine to speed up the regulatory review process.

The company has been racing to develop a safe and effective vaccine against the novel coronavirus that has killed more than 288,000 people globally. It expects to start a late-stage study of the vaccine early in the northern hemisphere summer...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now